Developing novel drugs for medulloblastoma
This research focuses on the development of novel drugs for the treatment of childhood brain tumours.
Super-fit immune cells to seek and destroy bone cancer
Osteosarcoma bone cancer affects teenagers, around half of whom die within 5-years of diagnosis. We think we can solve these problems by modifying immune cells called “gamma-delta T-cells”.
Developing a 'better than MRI scan' test for ependymoma
Half of patients Ependymoma (EPN) with no disease after treatment on MRI relapse within 2 years. This suggests that they have low level or minimal residual disease (MRD). Developing an accurate MRD detection test could help improve survival.
‘ALL’ about metabolism: repurposing drugs for acute lymphoblastic leukaemia
Examining whether a group of drugs called gliflozins could be used to treat T-ALL
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
Evaluating the use of novel treatments in combination with current maintenance therapies for the on-going treatment of high-risk neuroblastomas
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study